In trading on Thursday, shares of Leidos Holdings Inc (Symbol: LDOS) crossed above their 200 day moving average of $98.88, changing hands as high as $100.09 per share. Leidos Holdings Inc shares are currently trading up about 2.1% on the day. The chart below shows the one year performance of LDOS shares, versus its 200 day moving average: Looking at the chart above, LDOS's low point in its 52 week...
In trading on Thursday, shares of Leidos Holdings Inc (Symbol: LDOS) crossed above their 200 day moving average of $98.88, changing hands as high as $100.09 per share. Leidos Holdings Inc shares are currently trading up about 2.1% on the day. The chart below shows the one year performance of LDOS shares, versus its 200 day moving average: Looking at the chart above, LDOS's low point in its 52 week range is $81.07 per share, with $111.12 as the 52 week high point — that compares with a last trade of $99.39. The LDOS DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
FARGO, N.D., March 06, 2026 (GLOBE NEWSWIRE) -- NI Holdings, Inc. (“NI Holdings,” or the “Company,” NASDAQ: NODK) announced today results for the year ended December 31, 2025. Summary of Year-End 2025 Results (All comparisons vs. continuing operations for the year-end 2024, unless noted otherwise) Direct written premiums were $54.1 million for the quarter, down 26% compared to the prior year quart...
FARGO, N.D., March 06, 2026 (GLOBE NEWSWIRE) -- NI Holdings, Inc. (“NI Holdings,” or the “Company,” NASDAQ: NODK) announced today results for the year ended December 31, 2025. Summary of Year-End 2025 Results (All comparisons vs. continuing operations for the year-end 2024, unless noted otherwise) Direct written premiums were $54.1 million for the quarter, down 26% compared to the prior year quarter, and $289.8 million for the full year, down 15.3% compared to the prior year. The declines in both periods were primarily driven by the strategic decision to reduce written premiums in the Non-Standard Auto segment. This was partially offset by growth in the Home and Farm segment from new business, rate increases, and higher property values in North Dakota, South Dakota, and Nebraska, though results in South Dakota were tempered by lower retention rates. Net earned premiums of $58.2 million, down 18.9% compared to prior year quarter, and full year net earned premiums of $270.7 million, down 12.7% compared to prior year. Combined ratio was 109.6% for the quarter, up 29.6 points compared to the prior year quarter, driven by unfavorable prior year reserve development in the Non-Standard Auto segment, lower net earned premiums in Non-Standard Auto following the strategic decision to exit Illinois, South Dakota, and Arizona, as well as increased severity on liability claims and related current year reserve strengthening in the Private Passenger Auto segment. Combined ratio was 109.9% for full year 2025, up 9.2 points compared to the prior year, primarily driven by unfavorable prior year development on liability loss reserves and lower net earned premiums in the Non-Standard Auto segment. Results in the Home and Farm segment were adversely affected by the historic second-quarter catastrophe event in North Dakota, which exceeded the Company’s $20 million reinsurance retention and triggered related reinstatement premiums, partially offset by favorable weather experience in South...
Rasi Bhadramani/iStock via Getty Images Consensus Expectations - Near The 2% Target The U.S. BLS is set to release the February CPI inflation report on March 11th. The consensus expectations are: The core CPI to increase by 0.2% MoM, which would be less than 0.3% MoM in January, and keep the annual core CPI unchanged at 2.5%, and The headline CPI inflation is to increase by 0.2% MoM, unchanged fro...
Rasi Bhadramani/iStock via Getty Images Consensus Expectations - Near The 2% Target The U.S. BLS is set to release the February CPI inflation report on March 11th. The consensus expectations are: The core CPI to increase by 0.2% MoM, which would be less than 0.3% MoM in January, and keep the annual core CPI unchanged at 2.5%, and The headline CPI inflation is to increase by 0.2% MoM, unchanged from January; however, due to base effects, this would push the annual CPI down from 2.5% to 2.4%. Thus, practically, based on these expectations, CPI inflation is very near the Fed's 2% target. Note, CPI inflation is generally around 50 bpt higher than the Fed's preferred PCE inflation measure. Trading Economics Other Inflation Measures Disagree However, other official inflation measures show a different picture. The PPI inflation has been actually heating up. Below is the chart of the annual Producer Prices Final Demand Less Foods, Energy, and Trade Services. This measure of PPI is at 3.4%, and it has been rising since June 2025, with the spike in October 2025, which is still in progress. This is likely due to tariffs. Trading Economics Below is the chart of the Core PCE Price Index Annual Change, and this is the Fed's preferred inflation measure. The core PCE is at 3%, with the spike in December 2025. Note, the core PCE is supposed to be at 2%. Trading Economics Thus, a cooling CPI inflation is not consistent with other official measures of inflation. Note, CPI inflation is heavily influenced by shelter inflation (rent), which has been falling, and that could be the difference. Based on the chart below, the national average rent was $1,626 per month, which is an increase of 0.4% over the last year - the lowest increase since 2016. Rents are falling as the vacancy rate is rising, currently at 8.6%, the highest since 2016. This is likely to continue due to slower population growth given the immigration policy, in addition to an increase in multifamily housing construction. Ap...
(RTTNews) - Microsoft has confirmed that its gaming division is developing a next-generation Xbox console, currently code-named Project Helix, signaling a new phase for the company's gaming hardware strategy. According to Microsoft, the upcoming console will focus on leading performance while introducing deeper integration between Xbox and PC gaming. The device is expected to support both Xbox tit...
(RTTNews) - Microsoft has confirmed that its gaming division is developing a next-generation Xbox console, currently code-named Project Helix, signaling a new phase for the company's gaming hardware strategy. According to Microsoft, the upcoming console will focus on leading performance while introducing deeper integration between Xbox and PC gaming. The device is expected to support both Xbox titles and PC games, marking a shift from previous Xbox consoles that primarily ran games designed specifically for the platform. While details about Project Helix remain limited, Microsoft indicated that more information could be revealed during the upcoming Game Developers Conference in San Francisco. The announcement comes as Microsoft's gaming business faces challenges. The company reported a 9 percent decline in gaming revenue and a 32 percent drop in hardware revenue in its latest earnings report. However, Microsoft continues to invest heavily in the gaming sector, highlighted by its $69 billion acquisition of Activision Blizzard in 2023 and a strong lineup of upcoming titles, including Fable expected in 2026. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Tesla (NasdaqGS:TSLA) is reallocating resources from its premium Model S and Model X lines toward production of its humanoid Optimus robot as part of a broader push into artificial general intelligence. Regulatory and legal pressures on Tesla’s Autopilot and...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Tesla (NasdaqGS:TSLA) is reallocating resources from its premium Model S and Model X lines toward production of its humanoid Optimus robot as part of a broader push into artificial general intelligence. Regulatory and legal pressures on Tesla’s Autopilot and Full Self Driving systems are intensifying, with authorities underscoring that the technology still requires continuous driver attention. At Tesla’s Berlin Gigafactory, union IG Metall did not secure a majority in the works council election, affecting how employee representation is structured at the site. For you as an investor, these moves indicate Tesla is positioning itself from a pure electric vehicle maker to a broader robotics and AI company while still operating under the scrutiny that comes with automated driving systems. The combination of robot development, AGI ambitions, and high profile driver assistance technologies places Tesla at the intersection of hardware, software, and regulation. In the future, the balance between capital and talent devoted to Optimus and AGI versus cars, batteries, and charging could influence how you think about Tesla’s risk profile and peer group. At the same time, regulatory outcomes on Autopilot and Full Self Driving, as well as how labor relations evolve in Europe, may shape Tesla’s cost structure, product rollout priorities, and operational flexibility. Stay updated on the most important news stories for Tesla by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Tesla. NasdaqGS:TSLA Earnings & Revenue Growth as at Mar 2026 📰 Beyond the headline: 3 risks and 1 thing going right for Tesla that every investor should see. Quick Assessment ⚖️ Price vs Analyst Target : At US$405.55 versus a consensus target of US$421.61, Tesla trades about 4% below analyst expectations. ❌ Sim...
Former world 100m champion Fred Kerley has been banned for two years for anti-doping whereabouts failures. A tribunal found Kerley was "negligent and, to a certain extent, reckless" in not adhering to anti-doping regulations, after the American recorded three whereabouts failures between 11 May and 6 December 2024. Kerley was provisionally suspended by the Athletics Integrity Unit (AIU) in August ...
Former world 100m champion Fred Kerley has been banned for two years for anti-doping whereabouts failures. A tribunal found Kerley was "negligent and, to a certain extent, reckless" in not adhering to anti-doping regulations, after the American recorded three whereabouts failures between 11 May and 6 December 2024. Kerley was provisionally suspended by the Athletics Integrity Unit (AIU) in August last year and missed September's World Championships in Tokyo. The 30-year-old's period of ineligibility will run until 11 August 2027 and his competitive results between 6 December 2024 and 12 August 2025 have been disqualified, including prize money, prizes and titles. Kerley has also been ordered to pay World Athletics £3,000 in legal fees and other expenses. The World Anti-Doping Code states an athlete cannot miss three anti-doping tests and/or filing failures within a 12-month period. The AIU said a Disciplinary and Appeals Tribunal did not consider a fourth alleged whereabouts failure by Kerley on 7 December, having already determined he committed a violation based on the first three.
Both Alphabet (GOOGL 0.75%)(GOOG 0.87%) and Nvidia (NVDA 2.94%) have established themselves as foundational pillars of the artificial intelligence (AI) revolution. But when looking ahead over a 10-year horizon, the question isn't whether both businesses will succeed -- it's which stock offers the better risk-adjusted path for investors from today's starting line. On the surface, Nvidia's momentum ...
Both Alphabet (GOOGL 0.75%)(GOOG 0.87%) and Nvidia (NVDA 2.94%) have established themselves as foundational pillars of the artificial intelligence (AI) revolution. But when looking ahead over a 10-year horizon, the question isn't whether both businesses will succeed -- it's which stock offers the better risk-adjusted path for investors from today's starting line. On the surface, Nvidia's momentum looks unstoppable. The semiconductor giant just reported another quarter of staggering growth. Yet beneath the headline numbers, the comparison isn't so simple. Ultimately, one of these two tech behemoths comes out ahead when comparing their business durability and valuation expectations. Alphabet: a cloud-computing catalyst Alphabet recently reported its fourth-quarter results for 2025, and the headline numbers were exceptional. The tech giant's revenue for the period rose 18% year over year to $113.8 billion. And the company's full-year revenue notably crossed the $400 billion mark for the first time in its history. But the real story for long-term investors is what is happening inside Google Cloud, the company's cloud computing business. Google Cloud revenue surged 48% year over year to $17.7 billion in Q4. Highlighting its scale, the segment is now operating at an annual run rate of more than $70 billion. Expand NASDAQ : GOOG Alphabet Today's Change ( -0.87 %) $ -2.61 Current Price $ 298.30 Key Data Points Market Cap $3.6T Day's Range $ 295.25 - $ 300.33 52wk Range $ 142.66 - $ 350.15 Volume 17M Avg Vol 22M Gross Margin 59.68 % Dividend Yield 0.28 % Additionally, this segment provides investors with visibility. Management noted during the company's earnings call that Alphabet's cloud backlog swelled by 55% quarter over quarter to a massive $240 billion. This soaring backlog is driven by strong demand for its cloud products, led by its enterprise AI offerings, including Gemini, which -- by the way -- is now processing over 10 billion tokens per minute for customers via d...
Key Points Alphabet's cloud backlog just surged 55% sequentially to $240 billion. Nvidia's data center revenue soared 75% year over year in its latest quarter. When comparing the two AI stocks, one is the clear winner. 10 stocks we like better than Alphabet › Both Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG) and Nvidia (NASDAQ: NVDA) have established themselves as foundational pillars of the artificial ...
Key Points Alphabet's cloud backlog just surged 55% sequentially to $240 billion. Nvidia's data center revenue soared 75% year over year in its latest quarter. When comparing the two AI stocks, one is the clear winner. 10 stocks we like better than Alphabet › Both Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG) and Nvidia (NASDAQ: NVDA) have established themselves as foundational pillars of the artificial intelligence (AI) revolution. But when looking ahead over a 10-year horizon, the question isn't whether both businesses will succeed -- it's which stock offers the better risk-adjusted path for investors from today's starting line. On the surface, Nvidia's momentum looks unstoppable. The semiconductor giant just reported another quarter of staggering growth. Yet beneath the headline numbers, the comparison isn't so simple. Ultimately, one of these two tech behemoths comes out ahead when comparing their business durability and valuation expectations. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Alphabet: a cloud-computing catalyst Alphabet recently reported its fourth-quarter results for 2025, and the headline numbers were exceptional. The tech giant's revenue for the period rose 18% year over year to $113.8 billion. And the company's full-year revenue notably crossed the $400 billion mark for the first time in its history. But the real story for long-term investors is what is happening inside Google Cloud, the company's cloud computing business. Google Cloud revenue surged 48% year over year to $17.7 billion in Q4. Highlighting its scale, the segment is now operating at an annual run rate of more than $70 billion. Additionally, this segment provides investors with visibility. Management noted during the company'searnings callthat Alphabet's cloud backlog swelled by 55% quarter over quarter to a massive...
Harvard Bioscience ( HBIO ) said on Friday it has approved a 1-for-10 reverse stock split of the company’s common shares, following authorization from shareholders at a special meeting held on March 6, 2026. The reverse stock split will take effect on March 13, 2026, intended at increasing the company’s share price to regain compliance with the Nasdaq Capital Market’s minimum bid requirement. No f...
Harvard Bioscience ( HBIO ) said on Friday it has approved a 1-for-10 reverse stock split of the company’s common shares, following authorization from shareholders at a special meeting held on March 6, 2026. The reverse stock split will take effect on March 13, 2026, intended at increasing the company’s share price to regain compliance with the Nasdaq Capital Market’s minimum bid requirement. No fractional shares will be issued in connection with the reverse split. The transaction will reduce the company’s outstanding common shares to about 4.47 million from roughly 44.72 million, while the total authorized share count will remain unchanged. Shares -4.19%. More on Harvard Bioscience Seeking Alpha’s Quant Rating on Harvard Bioscience Historical earnings data for Harvard Bioscience Financial information for Harvard Bioscience
Wearable Devices ( WLDS ) announced on Friday that it intends to effect a one-for-three reverse split of the company’s ordinary shares and its tradable warrants (the “Warrants”). The ordinary shares and warrants will continue to trade on the Nasdaq Capital Market under the existing symbols “WLDS” and “WLDSW,” respectively, and will begin trading on a split-adjusted basis when the market opens on M...
Wearable Devices ( WLDS ) announced on Friday that it intends to effect a one-for-three reverse split of the company’s ordinary shares and its tradable warrants (the “Warrants”). The ordinary shares and warrants will continue to trade on the Nasdaq Capital Market under the existing symbols “WLDS” and “WLDSW,” respectively, and will begin trading on a split-adjusted basis when the market opens on March 11, 2026. The primary purpose of the reverse share split is to increase the per-share trading price of the company's ordinary shares to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq. The reverse share split will adjust the number of issued and outstanding ordinary shares of the company from 10,593,227 ordinary shares to approximately 3,531,076 ordinary shares and the number of publicly held warrants from 98,589 warrants to approximately 32,863 warrants. WLDS -5.92% after hours to $0.7452. Source: Press Release More on Wearable Devices Seeking Alpha’s Quant Rating on Wearable Devices Financial information for Wearable Devices
Key Points Sold 1,908,011 shares; estimated trade value ~$109.65 million based on quarterly average pricing. Quarter-end position value decreased by $109.65 million, reflecting full exit and price movement. Transaction represented 1.2% of Hood River's reported 13F assets under management. Post-trade, Hood River held zero shares in Varonis Systems, with a stake value of $0. The position previously ...
Key Points Sold 1,908,011 shares; estimated trade value ~$109.65 million based on quarterly average pricing. Quarter-end position value decreased by $109.65 million, reflecting full exit and price movement. Transaction represented 1.2% of Hood River's reported 13F assets under management. Post-trade, Hood River held zero shares in Varonis Systems, with a stake value of $0. The position previously accounted for 1.3% of the fund's AUM as of the prior quarter. 10 stocks we like better than Varonis Systems › Hood River Capital Management exited its entire stake in Varonis Systems (NASDAQ:VRNS), selling 1,908,011 shares in the fourth quarter for an estimated $109.65 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. What happened According to a recent SEC filing dated February 17, 2026, Hood River Capital Management LLC liquidated its entire position in Varonis Systems during the fourth quarter of 2025. The firm sold all 1,908,011 shares for an estimated transaction value of $109.65 million, based on the average share price during the quarter. The quarter-end value of the stake decreased by $109.65 million, reflecting both the share sale and stock price movement. What else to know Hood River sold out of Varonis Systems, which now represents 0% of its 13F assets under management. Top holdings after the filing: NASDAQ:APLD: $540.36 million (5.9% of AUM) NYSE:MTZ: $322.50 million (3.5% of AUM) NASDAQ:DAVE: $247.08 million (2.7% of AUM) NYSE:FIX: $229.46 million (2.5% of AUM) NASDAQ:KTOS: $208.41 million (2.3% of AUM) As of February 16, 2026, shares of Varonis Systems were priced at $25.36, down 41.99% over the past year. That performance trailed the S&P 500 by 53.79 percentage points over the same period. The position was previously 1.3% of the fund's AUM as of the prior quarter. Company Overview Metric Value Market Capitalization $2.99 billion Employees 2,406 Revenue (TTM) $623.53 million Net Income (TTM) ($129.32 million) Company Sna...
Key Points Kettle Hill Capital Management initiated a 1,716,381-share position in SentinelOne; estimated trade value was $25.75 million based on quarterly average pricing. The quarter-end position value increased by $25.75 million, reflecting the new holding and stock price movement. This change represents 5.74% of the fund’s reportable U.S. equity assets under management (AUM). The SentinelOne st...
Key Points Kettle Hill Capital Management initiated a 1,716,381-share position in SentinelOne; estimated trade value was $25.75 million based on quarterly average pricing. The quarter-end position value increased by $25.75 million, reflecting the new holding and stock price movement. This change represents 5.74% of the fund’s reportable U.S. equity assets under management (AUM). The SentinelOne stake makes it Kettle Hill's fourth-largest holding. 10 stocks we like better than SentinelOne › On February 13, 2026, Kettle Hill Capital Management disclosed a new position in SentinelOne (NYSE:S). What happened According to a Securities and Exchange Commission (SEC) filing dated February 13, 2026, Kettle Hill Capital Management, LLC opened a new position in SentinelOne, acquiring 1,716,381 shares. The estimated transaction value was $25.75 million, calculated using the average share price for the quarter. The quarter-end value of the SentinelOne stake also totaled $25.75 million, reflecting both the trade and underlying price changes. What else to know The new SentinelOne stake represents 5.74% of Kettle Hill Capital Management’s 13F reportable AUM. Top holdings after the filing include: NYSE:ESTC: $29.69 million (about 6.6% of AUM) NYSE:U: $29.06 million (about 6.5% of AUM) NASDAQ:WYNN: $25.89 million (about 5.8% of AUM) NYSE: S: $25.75 million (5.7% of AUM) NYSE: VZ: $23.49 million (5.2% of AUM) As of February 13, 2026, SentinelOne shares were priced at $13.87, down 44.5% over the prior year, underperforming the S&P 500 by 56.25 percentage points. Company/Etf overview Metric Value Price (as of market close February 13, 2026) $13.87 Market Capitalization $4.71 billion Revenue (TTM) $955.65 million Net Income (TTM) ($411.29 million) Company/Etf snapshot Offers the Singularity XDR Platform, an AI-powered solution for autonomous threat prevention, detection, and response across endpoints, cloud workloads, and IoT devices. Generates revenue primarily through subscription-base...
A flight information screen at Hong Kong International Airport on March 4, 2026 shows an Emirates flight from Dubai scheduled to arrive that evening. Photo: VCG Major Middle Eastern airlines are resuming flights, creating a brief window for stranded travelers to leave the conflict-stricken region, as China's Foreign Ministry urged its citizens to seize the opportunity to evacuate. Etihad Airways o...
A flight information screen at Hong Kong International Airport on March 4, 2026 shows an Emirates flight from Dubai scheduled to arrive that evening. Photo: VCG Major Middle Eastern airlines are resuming flights, creating a brief window for stranded travelers to leave the conflict-stricken region, as China's Foreign Ministry urged its citizens to seize the opportunity to evacuate. Etihad Airways on Friday announced it would resume commercial flights to 70 international destinations from March 6 to March 19, including Beijing, Hong Kong and Taipei. A day earlier, Emirates said it was operating a reduced schedule to 75 destinations, while Qatar Airways began running a limited number of “relief flights.”
The US unexpectedly lost jobs in February while unemployment edged up, government data showed Friday, piling pressure on President Donald Trump’s economic agenda as key midterm elections approach. The world’s biggest economy shed 92,000 jobs last month, in a sharp reversal from the job growth of 126,000 in January, the Labour Department said. The unemployment rate, meanwhile, crept up to 4.4 per c...
The US unexpectedly lost jobs in February while unemployment edged up, government data showed Friday, piling pressure on President Donald Trump’s economic agenda as key midterm elections approach. The world’s biggest economy shed 92,000 jobs last month, in a sharp reversal from the job growth of 126,000 in January, the Labour Department said. The unemployment rate, meanwhile, crept up to 4.4 per cent from 4.3 per cent. Advertisement White House economic adviser Kevin Hassett insisted Friday that the US economy remained “really strong”, telling CNBC that observers should consider the average job growth over a few months instead of focusing on monthly fluctuations. But Chuck Schumer, who leads the Senate’s Democratic minority, swiftly criticised the report as a “blaring alarm” that Trump’s economy was “deteriorating rapidly”. Advertisement “Tariffs are increasing costs, gas prices are spiking, and jobs are evaporating,” Schumer said.
Oracle Corp. and OpenAI have scrapped plans to expand a flagship artificial intelligence data center in Texas after negotiations dragged over financing and OpenAI’s changing needs. The collapsed talks created an opening for Meta Platforms Inc. to step in and consider leasing the planned expansion site in Abilene, Texas, from developer Crusoe, according to people familiar with the matter. Nvidia Co...
Oracle Corp. and OpenAI have scrapped plans to expand a flagship artificial intelligence data center in Texas after negotiations dragged over financing and OpenAI’s changing needs. The collapsed talks created an opening for Meta Platforms Inc. to step in and consider leasing the planned expansion site in Abilene, Texas, from developer Crusoe, according to people familiar with the matter. Nvidia Corp., the leading AI chipmaker, helped facilitate Meta’s discussions with the developer, said the people, who asked not to be identified because the talks are private. Most Read from Bloomberg The shifting plans underscore the complexity of building out AI data centers, which are expected to cost in the tens of billions of dollars and require cooperation from a wide swath of partners. WATCH: Oracle Corp. and OpenAI have scrapped plans to expand a flagship artificial intelligence data center in Texas.Source: Bloomberg The campus being developed by Crusoe in Abilene is part of the highly publicized Stargate project, which was announced last year at the White House with President Donald Trump. While the 1,000-acre site continues to be built, and several parts are up and running, Oracle and OpenAI elected not to go forward with tentative plans to lease a large expansion, the people said. Oracle and OpenAI are using Nvidia’s AI semiconductors at the Stargate site. With Crusoe seeking a tenant, Nvidia became involved to ensure its products would still fill the expanded data center rather than that of rival Advanced Micro Devices Inc., said the people. Nvidia paid a $150 million deposit to Crusoe and began helping court Meta as a tenant for the expansion, the people said. Oracle agreed last July to develop 4.5 gigawatts of data center capacity for OpenAI. That deal remains on track, and the companies have announced a number of projects in other locations, such as one near Detroit owned by Related Digital. Shares of Oracle gave up earlier gains and slipped 1.2% to $152.96 at the clo...
Powell Industries ( POWL ) has approved a three-for-one forward stock split of the company’s common stock. The company also approved a proportionate increase in the number of authorized shares of common stock to accommodate the stock split. The company expects that the stock split will increase the number of shares of the company’s outstanding common stock from ~12.1 million shares to ~36.4 millio...
Powell Industries ( POWL ) has approved a three-for-one forward stock split of the company’s common stock. The company also approved a proportionate increase in the number of authorized shares of common stock to accommodate the stock split. The company expects that the stock split will increase the number of shares of the company’s outstanding common stock from ~12.1 million shares to ~36.4 million shares. POWL +0.15% after hours to $483.3. Source: Press Release More on Powell Industries Powell Industries' Melt Up Exceeds Its Fundamentals - Beneficiary Of Electrification Boom Powell Industries: The Price Level I Load Up At Powell Industries, Inc. 2026 Q1 - Results - Earnings Call Presentation Powell Industries targets robust 2026 growth with $1.6B backlog and record new orders as data center and utility markets accelerate Powell Industries tops earnings estimates but misses revenue in fiscal Q1
Kirk Fisher/iStock Editorial via Getty Images Lowe's Companies, Inc. ( LOW ) is a home improvement retailer in the United States, providing products for construction, maintenance, repair, or decor. I started covering the company back in May 2022 with an initial neutral rating, primarily citing macroeconomic headwinds related to the housing market and consumer confidence. Since then almost 4 years ...
Kirk Fisher/iStock Editorial via Getty Images Lowe's Companies, Inc. ( LOW ) is a home improvement retailer in the United States, providing products for construction, maintenance, repair, or decor. I started covering the company back in May 2022 with an initial neutral rating, primarily citing macroeconomic headwinds related to the housing market and consumer confidence. Since then almost 4 years have passed, and the macroeconomic environment remains just as challenging as it was back then. Analysis history (Author) Over the period of my coverage, LOW performed pretty much in line with the broader market ( SPY ) and the consumer discretionary sector ( XLY ), at least up to late 2024, when LOW started to slightly underperform. Data by YCharts The aim of my article today is to give an updated view on my previous investment thesis. I will be looking at a set of economic indicators - including consumer confidence and existing home sales - to gauge the macroeconomic landscape, along with the firm's latest quarterly earnings results. Last, but not least, I will also comment on the valuation briefly to see whether the previously established hold rating is still warranted or not. Earnings In the most recent quarter, LOW managed to beat analyst estimates on both the top and bottom lines. Revenue came in at $20.6 billion, 11% above last year's figure and $247.5 million above analyst expectations. Adjusted diluted EPS was $1.98, compared to the expectations of $1.94. While the growth definitely sounds attractive, there are a few key points that I need to highlight. Comparable sales growth was only a small portion of the total sales growth. Comps increased only 1.3% year-over-year. It means that LOW's sales growth is not driven by organic, same-store revenue growth due to the higher demand for their products, but by new store openings and acquisitions. Two relevant acquisitions from last year were Foundation Building Materials and Artisan Design Group. Income statement (Lowe's)...
imaginima/E+ via Getty Images The number of oil and gas rigs actively drilling in the U.S. added 1 to 551, rising for the first time in four weeks, Baker Hughes said Friday in its latest weekly survey . During the week ended March 6, the number of active drilling rigs targeting crude oil in the U.S. rose by 4 to 411, the highest level since early February, gas rigs dropped 2 to 132, and 8 rigs wer...
imaginima/E+ via Getty Images The number of oil and gas rigs actively drilling in the U.S. added 1 to 551, rising for the first time in four weeks, Baker Hughes said Friday in its latest weekly survey . During the week ended March 6, the number of active drilling rigs targeting crude oil in the U.S. rose by 4 to 411, the highest level since early February, gas rigs dropped 2 to 132, and 8 rigs were classified as miscellaneous. The total rig count was down by 41, or 6.9%, from the same time last year, with oil rigs down 75, or 15.4%, and gas rigs up 31, or 30.7%, compared to a year ago. The number of rigs targeting oil in the Permian Basin gained 2 to 241, the oil rig count in the Eagle Ford jumped by 4 to 32, and the Williston Basin lost 1 rig to 27. ETFs: ( USO ), ( UCO ), ( SCO ), ( USL ), ( DBO ), ( DRIP ), ( GUSH ), ( USOI ), ( UNG ), ( BOIL ), ( KOLD ), ( UNL ), ( FCG ) More on crude oil How The Mideast War Impacts Oil, Gas, And U.S. Stocks $150 Oil - This Is What It Would Take Middle East Escalation Rattles Energy Markets
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 46,000 shares of Class A common stock and restricted stock units (RSUs) underlying 25,875...
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 46,000 shares of Class A common stock and restricted stock units (RSUs) underlying 25,875 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on March 3, 2026 has an exercise price per share equal to $39.30, Vera Therapeutics’ closing trading price on March 3, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of either February 20 or May 20, 2026, depending on the start date of the new employee, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Vera Therapeutics Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead...
WeBond Creations/iStock via Getty Images The last time I spoke about Arcturus Therapeutics Holdings Inc. ( ARCT ) it was with a Seeking Alpha article entitled " Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data ." With respect to this article, I noted that this company was gearing up to release interim results from its LUNAR-CF study using its once-daily inhaled messenger RNA...
WeBond Creations/iStock via Getty Images The last time I spoke about Arcturus Therapeutics Holdings Inc. ( ARCT ) it was with a Seeking Alpha article entitled " Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data ." With respect to this article, I noted that this company was gearing up to release interim results from its LUNAR-CF study using its once-daily inhaled messenger RNA [mRNA] therapeutic candidate ARCT-032 for the treatment of patients with Cystic Fibrosis [CF]. The hope was that this drug would benefit these CF patients who don't respond to currently available CFTR modulatory therapy. Unfortunately, this was not the case, as it was noted in the interim analysis that these patients who received 10 mg ARCT-032 for 28 days did not achieve a clinically meaningful improvement in FEV1. With that being said, the last time around I had rated this stock as a "Strong Buy" rating. Today, I'm downgrading the stock to a "Hold" rating. Why this particular rating? The reason why, first and foremost, is that this program is not entirely gone. There is a chance to specifically help a portion of Class I CF patients who benefited from ARCT-032, which I will be going over below. The point is that Arcturus is moving on to a 12-week phase 2 study using this candidate to treat this specific group of CF patients. A small catalyst opportunity is at play here, as this mid-stage trial is expected to start in the 1st half of 2026. There is a second reason why I'm still maintaining a "Hold" rating on this stock and not an outright "Sell" rating. It is because the company is pressing forward with a late-stage program using its other mRNA candidate, ARCT-810, for the treatment of patients with ornithine transcarbamylase [OTC] deficiency. Why is this program important? The company has already established being able to bring glutamine levels from abnormal to normal. Plus, a few other evaluated measures I'm going to go over below. Plus, there is actually a catalyst for ...
Cleveland Fed President Beth Hammack expects interest rates to be on hold for quite some time. She speaks to Bloomberg's Michael McKee in New York. (Source: Bloomberg)
Cleveland Fed President Beth Hammack expects interest rates to be on hold for quite some time. She speaks to Bloomberg's Michael McKee in New York. (Source: Bloomberg)
master1305/iStock via Getty Images Investment Overview The stock of Tango Therapeutics, Inc. ( TNGX ) surged in value yesterday, rising from ~$12.4, to $17.4 per share, a gain of ~43%, as the Boston, Massachusetts based biotech reported its Q4 and annual earnings, and shared business updates. After yesterday's gains, Tango stock is now up an impressive 285% since my last note on the company in Jun...
master1305/iStock via Getty Images Investment Overview The stock of Tango Therapeutics, Inc. ( TNGX ) surged in value yesterday, rising from ~$12.4, to $17.4 per share, a gain of ~43%, as the Boston, Massachusetts based biotech reported its Q4 and annual earnings, and shared business updates. After yesterday's gains, Tango stock is now up an impressive 285% since my last note on the company in June last year , in which I awarded stock a Buy rating, and up 31% since my original Buy call in January 2024 . To remind ourselves - as per Tango's 2025 annual report / 10-K submission : We are currently focused on clinical development of two MTAP-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, our next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). There are a couple of other assets in Tango's pipeline, as illustrated in the below slide (taken from a January 2025 investor presentation ). Tango Therapeutics pipeline overview (presentation) After my first note on Tango, I discussed how positive data from a rival PRMT5-targeting asset developed by Mirati Therapeutics - acquired by Bristol-Myers Squibb ( BMY ) in a $5.8bn deal in 2023 - six confirmed objective responses in a study of 18 patients with solid tumors harboring MTAP deletions - had got the market excited about the this drug class, and triggered gains for Tango. I concluded that: There may be opportunities to buy Tango stock at much cheaper prices that today's price of $13 per share, as the stock is clearly volatile and influenced by the progress of other drug developers, rightly or wrongly. Inevitably, however, if Tango is on the right track, its valuation ought to soar. I would urge prospective investors to be patient with Tango, however, and let the four clinical studies progress. With no dilution likely unless candidates return positive, share price needle moving dat...